2007
DOI: 10.1016/j.lfs.2006.11.024
|View full text |Cite
|
Sign up to set email alerts
|

Nucleotide metabolizing ecto-enzymes in Walker 256 tumor cells: Molecular identification, kinetic characterization and biochemical properties

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
17
0
1

Year Published

2008
2008
2020
2020

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 20 publications
(19 citation statements)
references
References 58 publications
1
17
0
1
Order By: Relevance
“…The next protocol was performed to assess E-NTPDase activity in aortic homogenate preparations in the presence or absence of Gd. Several studies have reported the ability of Gd to decrease nucleotide hydrolysis (6,22,23). In the present study, we observed that Gd was capable of inhibiting both ATP and ADP hydrolysis.…”
Section: Discussionsupporting
confidence: 66%
“…The next protocol was performed to assess E-NTPDase activity in aortic homogenate preparations in the presence or absence of Gd. Several studies have reported the ability of Gd to decrease nucleotide hydrolysis (6,22,23). In the present study, we observed that Gd was capable of inhibiting both ATP and ADP hydrolysis.…”
Section: Discussionsupporting
confidence: 66%
“…The Walker 256 cells were resuspended in a buffer containing 50 mM of HEPES (pH 7.5), 5.0 mM of KCl, 135 mM of NaCl, and 10 mM of dextrose. The cell suspensions with 98% viability were obtained from the ascitic fluid (Buffon et al 2007a). A Walker 256 tumor cell ascitic suspension (5 × 10 6 cells in 0.25 ml of Ringerlactate solution) was inoculated at a single dorsal subcutaneous site in the dorsolumbar region of the tumor-bearing group.…”
Section: Walker 256 Tumor Cellsmentioning
confidence: 99%
“…The Walker 256 tumor is a model that has been extensively used in cancer research (Guaitani et al 1982;He et al 2003;Piffar et al 2003;Ikeda et al 2004, Buffon et al 2007a. We have been using this model to evaluate the role of purinergic system in tumor biology.…”
Section: Introductionmentioning
confidence: 99%
“…[17][18][19] Recent studies show that CD39 is involved in the progression of AIDS [20][21][22] and is required for the pathological angiogenesis and progression of tumors. [23][24][25][26][27][28][29] This intense and multifunctional physiological integration of NTPDase1 has led to its identification both as a drug target and as a drug itself. Specific NTPDase1 inhibitors would constitute a potential clinical therapeutic in the treatment of cancer and immune deficiency diseases.…”
Section: Introductionmentioning
confidence: 99%